ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record15 judgments2 judges (our rules as one)1 record change seen4 read an older version
Claude Opus 5.5Our rulesRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07043725A Clinical Study ofNeoadjuvant Treatment WithTQB2102 for Injection forHuman Epidermal GrowthFactor Receptor 2 (HER2)Positive Breast CancerChia Tai Tianqing PharmaceuticPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Nov 2 · Our nightly check · Reading set asideNov 3 · Our nightly check · Read againRead againCONDITIONSBreast NeoplasmsNo longer in the registry's filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionDRUGSAnti-HER2/Topoisomerase I I…Entry “TQB2102 for injection”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedTestedTrastuzumabEntry “Trastuzumab injection and Pert…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorPertuzumabEntry “Trastuzumab injection and Pert…›Nov 2 · Claude Opus 5.5 · ComparatorNov 3 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorDocetaxelEntry “Trastuzumab injection and Pert…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparatorCarboplatinEntry “Trastuzumab injection and Pert…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Our role rule · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “TQB2102 for injection”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Claude Opus 5.5TestedRead an older version
Nov 2TrastuzumabClaude Opus 5.5ComparatorRead an older version
Nov 2PertuzumabClaude Opus 5.5ComparatorReplaced
Nov 2DocetaxelClaude Opus 5.5ComparatorRead an older version
Nov 2CarboplatinClaude Opus 5.5ComparatorRead an older version
Nov 2The record itselfClinicalTrials.gov recordVersion of 2026-11-02Record change
Nov 2The record itselfOur nightly checkReading set asideCurrent
Nov 3The record itselfOur nightly checkRead againCurrent
Nov 3PertuzumabClaude Opus 5.5ComparatorCurrent
Nov 14Breast NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 18Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Our role ruleTestedCurrent
Nov 18TrastuzumabOur role ruleComparatorCurrent
Nov 18PertuzumabOur role ruleComparatorAgrees
Nov 18DocetaxelOur role ruleComparatorCurrent
Nov 18CarboplatinOur role ruleComparatorCurrent
As of nowBreast NeoplasmsOur main-condition rule (R9)Main conditionCurrent